ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Karlan To Succeed Hoskins As Chairman, DOD Ovarian Cancer Program Advisory Panel.

July 27, 2001

William Tipping New ACS Executive VP; Murphy To Replace Holleb, Laszio Takes Rauscher’s Position

March 4, 1988

Breast Cancer Patients Track Symptoms With Digital Device

September 25, 2009

In Brief: NCI Still Undecided Over Small Hospital Segment Of CHOP; Multihospital Proposals Review Nov. 14-15

November 2, 1979

Virus Studies Approved By DCE Board for $2.5 Mil. In First Year

November 3, 1989

T-Cell Vaccines Cut Time To Protective Immunity

November 25, 2005